慢性肾脏病（CKD）是难治性疾病，最新的“肠-肾轴”理论认为，肠源性尿毒症毒素硫酸吲哚酚(IS)与CKD的进展及并发症有密切关系。通腑化浊凉血方是赵绍琴教授和彭建中教授治疗CKD的基本方，疗效确切，具有重要价值。该方的核心思想为“通腑导滞、化浊排毒、凉血解毒”，以消除蓄积在体内的“湿热毒”邪，保护肾功能。这点与“肠-肾轴”理论有契合之处。我们认为，通腑化浊凉血方治疗CKD的可能机制之一是通过干预“肠-肾轴”中IS的相关肾损害机制。为此，我们拟在慢性肾衰竭大鼠模型中，观察通腑化浊凉血方对IS的产生、吸收和肾毒性作用的影响，初步阐明通腑化浊凉血方对IS所引起的相关肾损伤的保护机制。本课题的研究成果将为IS的清除策略和CKD的治疗方案提供新思路，发扬中医药的优势。

Chronic kidney disease (CKD) is a refractory disease. The latest studies find that uremic toxin indoxyl sulfate(IS), derived from intestinal tract, being a potent role in the progress of CKD. Tongfuhuazhuoliangxue(THL) Decoction is a basic prescription that used by professor Zhao Shaoqin and professor Peng Jianzhong for treating CKD. This therapy's curative effect has been confirmed. The core thought of THL Decoction is cooling the blood and dissipating blood stasis, purgation and eliminating turbid, and excretion of toxin, in order to clear up dampness-heat toxin in the body. This point fits in the“gut-kidney axis”theory. In our oppion, the therapeutic mechanism of THL Decoction might be protecting from enterogenous uremic toxin's assosiated kidney impairment. So, we plan to measure indoxyl sulfate’s serum concentration and its renal toxicities on Epithelial Mesenchymal Transition (EMT), Klotho gene expression, ROS production and monocyte/macrophage infiltration in rat with THL Decoction，to clarify the mechanism of THL Decoction on CKD and indoxyl sulfate. The findings in our research will provide a new way for elimination toxins and treating CKD.

慢性肾脏病（CKD）是难治性疾病，“肠-肾轴”假说认为，肠源性尿毒症毒素硫酸吲哚酚(IS)与CKD的进展及并发症有密切关系。通腑化浊凉血方是赵绍琴教授和彭建中教授治疗CKD的基本方，为了阐明该方剂对肾脏的保护作用与肠道菌群及IS的关系，我们进行了该方在慢性肾衰竭大鼠的药效研究，肠道菌群研究和网络药理学研究。本研究发现通腑化浊凉血方能够调节慢性肾衰竭模型大鼠肠道菌群，尤其是减少拟杆菌属的相对丰度，从而抑制血清中硫酸吲哚酚的合成，发挥缓解慢性肾脏衰竭后肠源性毒素带来的肾损害。这一过程中可能涉及疾病网络的多个核心靶点蛋白和多个重要信号通路。本课题的研究成果将为IS的清除策略和CKD的治疗方案提供新思路，为发扬中医药的优势攻克慢性肾脏病提供实验依据。